Myelodysplastic Syndromes (MDS)

Rory Shallis, MD

Institution
Moffit Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About

Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital. He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. Dr. Shallis also maintains

2025 ASH Updates: Lower Risk MDS

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Akriti Jain, MD
In this webinar, Dr. Akriti Jain discusses research most relevant to patients reported over the past year on the biology and treatment of Lower Risk MDS. These studies were presented at the American Society of Hematology (ASH) 2025 meeting, and their findings will be explained…

Secondary AML

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Jayastu Senapati, MBBS, MD, DM
In this webinar, Dr. Jayastu Senapati discusses the diagnosis of secondary AML from MDS, treatment options available to patients and symptom management. Questions were asked by the online audience, and Dr. Senapati answered them clearly.

FLT3-ITD measurable residual disease from the QuANTUM-First trial

Original Publication Date
Article Source
External Web Content

Abstract QuANTUM-First was a randomized trial that demonstrated that the addition of quizartinib, a potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, to induction and consolidation chemotherapy, followed by monotherapy maintenance, improved the survival for…

Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study

Original Publication Date
Article Source
External Web Content

Abstract The intensity of the conditioning regimen in hematopoietic stem cell transplantation (HSCT) correlates with the risk of relapse, however its potential benefit may be outweighed by the associated risk of toxicity. The addition of total marrow irradiation (TMI) to…

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study

Original Publication Date
Article Source
External Web Content

ABSTRACT The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease…

Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.